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Suboptimal adherence to pharmacological treatment of asthma and chronic obstructive pulmo-
nary disease (COPD) has adverse effects on disease control and treatment costs. The reasons
behind non-adherence revolve around patient knowledge/education, inhaler device conve-
nience and satisfaction, age, adverse effects and medication costs. Age is of particular
concern given the increasing prevalence of asthma in the young and increased rates of non-
adherence in adolescents compared with children and adults. The correlation between adher-
ence to inhaled pharmacological therapies for asthma and COPD and clinical efficacy is posi-
tive, with improved symptom control and lung function shown in most studies of adults,
adolescents and children. Satisfaction with inhaler devices is also positively correlated with
improved adherence and clinical outcomes, and reduced costs. Reductions in healthcare utili-
sation are consistently observed with good adherence; however, costs associated with general
healthcare and lost productivity tend to be offset only in more adherent patients with severe
disease, versus those with milder forms of asthma or COPD. Non-adherence is associated with4711; fax: þ358 94716500.
fi (M.J. Ma¨kela¨).
3 Published by Elsevier Ltd.
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1482 M.J. Ma¨kela¨ et al.higher healthcare utilisation and costs, and reductions in health-related quality of life, and re-
mains problematic on an individual, societal and economic level. Further development of mea-
sures to improve adherence is needed to fully address these issues.
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Asthma and chronic obstructive pulmonary disease (COPD)
are two of the leading causes of morbidity, mortality and
economic burden worldwide.1 Approximately 235 million
people are thought to suffer from asthma globally,2 and 65
million are affected by moderate-to-severe COPD.1 The
World Health Organization (WHO) estimates that chronic
respiratory diseases represent 5% of total disease burden
and 8.3% of chronic disease burden worldwide, accounting
for more than 4 million deaths each year.1 COPD is ex-
pected to be the third leading cause of mortality by 2030.1
The burden of chronic respiratory diseases has major
adverse effects on the quality of life and ability of affected
individuals. Indeed, asthma and COPD are ranked 22nd and
10th, respectively, in terms of the leading causes of disease
burden when assessed using disability-adjusted life years.2
Comorbidities are significant contributors to the individual,
societal and economic burden of asthma and COPD.3e5
Further compounding the burden of these conditions are
their increasing prevalence, especially in children, adoles-
cents, the elderly and those from poorer countries.1
Unsurprisingly, the economic cost associated with COPD
and asthma is considerable. For COPD, the associated costs
are of crucial importance given the ageing population and
the expected corresponding increase in the prevalence of
the condition. Cost estimates for asthma vary, and have
been shown to increase with disease severity.6 A Finnish
analysis suggests that 1e2% of total healthcare expenditure
across industrialised nations is attributable to asthma.7
Although data from low- and middle-income countries are
lacking, in the USA alone annual COPD-associated costs
were more than $US32 billion in 2005.8 Given the increasing
prevalence of asthma and COPD, and the relationship be-
tween cost and disease severity, effective treatment and
management of these diseases is crucial in improving clin-
ical and economic outcomes.A variety of effective treatment options exist for pa-
tients with asthma and COPD, but long-term adherence to
medication is required for treatment success.9,10 Poor pa-
tient adherence to therapy can have detrimental effects on
outcomes, resulting in higher healthcare costs.11 Regardless
of illness type, poor adherence (often defined as 80%
adherence) is one of the main factors responsible for failure
to achieve treatment goals, and may also carry a large
economic burden as a result of increased healthcare costs
and unused medications. Given the intrinsic connection
between adherence, clinical outcomes and economic cost,
this review examines adherence issues in asthma and COPD,
factors that affect adherence, including evidence for cor-
relations between the correct use of inhaler devices and
improved adherence, effects of adherence on clinical effi-
cacy and costs/health outcomes in patients receiving
inhaled therapies for asthma or COPD.
A search of MEDLINE and EMBASE was conducted using
the following criteria: asthma [drug therapy] OR chronic
obstructive pulmonary disease [drug therapy] AND (patient
compliance OR medication adherence OR patient adher-
ence OR non-adherence OR patient preference OR patient
satisfaction). Results were limited to English language
publications of clinical studies published between January
2000 and April 2012; no other specific inclusion/exclusion
criteria were applied. An additional manual search of
PubMed was conducted for comprehensiveness using the
following key words: asthma, chronic obstructive pulmo-
nary disease and adherence. The same limitations were
applied as noted above. The resulting reference lists were
hand searched, and a further three relevant papers were
identified for inclusion. In total, 99 relevant papers were
identified for analysis. It should be noted that there was a
distinct lack of published material related to non-
adherence due to comorbidities in the elderly; therefore,
this topic was not covered in-depth. Furthermore, the aim
of this literature review was to examine the evidence for
Fig. 1 Most commonly used measures of adherence in studies
investigating inhaled asthma/chronic obstructive pulmonary
disease therapies from 2000 to 2012. Total percentage may not
add up to 100% as studies may have used more than one
adherence measure.
Table 1 Factors associated with poor adherence (adapted
from GINA Report, 2011 update).9
Drug factors Non-drug factors
Difficulties with
inhaler devices
Misunderstanding or lack
of instruction
Complex regimens Dissatisfaction with healthcare
professionals
Side effects Unexpressed/undiscussed
fears or concerns
Medication costs Inappropriate expectations
Dislike of medication(s) Poor supervision, training
or follow-up
Distant pharmacies Anger about condition
or treatment
Fears about side effects Underestimation of disease
severity
Cultural or religious issues
Stigmatisation
Forgetfulness/complacency
Attitude towards ill health
GINA, Global Initiative for Asthma.
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improved adherence. For this reason, detailed discussion of
adherence issues in specific subgroups of patients was
beyond the scope of this review.
Adherence issues in asthma and COPD
Adherence to treatment can be broadly defined as ‘the
extent to which a person’s behaviour corresponds with the
agreed recommendations from a healthcare provider’.12
Although the terms ‘compliance’ and ‘adherence’ are
often used interchangeably, not least in databases, there
are subtle differences between the two (‘compliance’ in-
fers a lack of patient involvement), and ‘adherence’ is
generally the preferred term.13 According to WHO esti-
mates, only 50% of patients receiving long-term pharma-
cotherapy for chronic diseases are adherent to treatment
(no precise definition of good versus poor adherence was
provided)12; adherence rates in asthma and COPD have
been shown to vary widely from 22% to 78%.14e17 Although
treatment success in asthma and COPD is largely dependent
upon medication adherence, suboptimal disease manage-
ment, including the failure of physicians to adhere to
treatment guidelines, also plays a part.18
Patients with asthma and COPD receive a lot of infor-
mation, including education on the disease processes, likely
comorbidities, risk factors, and the medications and de-
vices involved in treatment. In addition to starting phar-
macological treatment, patients may also be instructed to
cease smoking or make other lifestyle changes.18 These
factors may impact on adherence. The majority of studies
in asthma and COPD focus on pharmacological adherence,
as this is arguably the easiest factor to measure; however,
there is considerable variability in the definitions and
measurements of patient adherence across studies.
Methods of measurement include prescription refill adher-
ence (based on pharmacy records, manual/electronic
recording of collected prescriptions or national/provincial
database records), medication possession ratios (calculated
by dividing the number of days supplied for a medication by
the number of days in the study)19 and self-report measures
(including medication adherence rating scales such as the
Morisky Medication Adherence Scale20). More precise mea-
sures include electronic monitoring of dose actuations or
manual dose/pill-counting. The majority of studies in
asthma and COPD use prescription refill adherence or self-
report measures to measure pharmacological adherence,
although electronic dose monitoring is rising in popularity,
most likely because of its precision. Of the studies inves-
tigating adherence in asthma and COPD since 2000, the
most frequently used methods to assess adherence were
self-report measures (37.8%), prescription refill data
(32.8%) and electronic monitoring (19.3%) (Fig. 1). Many
studies employ both subjective and objective measures, for
instance a self-report scale in addition to prescription refill
adherence.21e36
Factors affecting adherence
The reasons for suboptimal adherence to inhaled asthma
and COPD therapies are multifaceted (Table 1). However,the negative association between suboptimal adherence
and poor disease control is clear.21,37e40 Factors thought to
influence adherence to inhaled medications include patient
age, level of education/knowledge about the conditions,
medication and delivery devices, time to onset of symptom
relief, symptom severity, regimen complexity (ease of use,
dosing frequency, number of medications), cost, comor-
bidities (additional medications, effect of other conditions
on adherence [e.g., depression]), adverse effects of
medication and poor doctor-patient communication.41e43
Adherence to inhaled therapies is worse than that seen
with oral44e47 or injected48 therapies in patients with
asthma, including children,26,49 and transdermal therapies
in patients with COPD.50 This is unsurprising given the usual
patient preference for easily administered medicines such
as once-daily oral tablets or once-weekly injections, as well
as the fact that patients may not believe that inhaled
medication is valuable. However, one recent study
demonstrated similar rates of adherence with the oral
1484 M.J. Ma¨kela¨ et al.leukotriene receptor antagonist montelukast and inhaled
corticosteroids (ICS) in paediatric patients with asthma,51
suggesting this is not always the case when the parents
are responsible for the anti-asthma treatment, which might
be different from situations in which adolescents and young
adults are taking care of the asthma management
themselves.
Age may play a role in adherence to treatment in asthma
andCOPD,with some studies showing older adults to bemore
adherent to treatment than younger adults,16,36,40 while
others have shown no difference.31 Adherence to inhaled
asthma therapy tends to be worse in adolescents than in
younger childrenand in adults.28,52e54 The reasons for below-
optimal adherence are often similar to those in adults, e.g.,
lack of knowledge and incorrect assumptions about treat-
ment/medication and illness, the consequences of which
depend on the severity of the disease. However, incorrect
assumptions about the illness may be more widespread if
more young patients are symptom-free. Denial (either of the
condition or of its severity), embarrassment and rebellion
may be more relevant to non-adherence in this popula-
tion.55,56 Peer expectations may also negatively influence an
adolescent’s adherence behaviour. Simply put, non-
adherence can be intentional (will not adhere) or non-
intentional (cannot adhere). Although it may be tempting
to assume that adolescents are more prone to the former
than the latter, true intentional non-adherence is a compli-
cated issue and very few patients neglect their condition for
the purpose of harming themselves deliberately.56
A recent study has suggested that educating parents
about their child’s allergic status and probable relationship
to the child’s asthma may improve adherence to inhaled
therapy.57 Parents of asthmatic children who underwent
skin prick testing were more likely to adhere to scheduled
continuity visits. This is the first evidence of such a finding,
and may have important implications for adherence in
children, and even adults. One may also speculate that
objective diagnostic tests confirming the presence of
asthma may modify the patient’s beliefs sufficiently for
them to see the importance of good adherence (often
defined as >80% adherence) to therapy. However, this is
the only study demonstrating such data, and this area re-
quires further research.Inhaler devices and adherence
Multiple-inhaler use has been associated with higher rates
of non-adherence than single-inhaler use in both asthma
and COPD patients e potentially because of the increased
complexity introduced by the additional inhaler(s).32,58e60
Although one study found that certain inhaler types may
be associated with higher rates of adherence than others in
patients with asthma receiving ICS,61 data in this area are
lacking and it is important to note that individual patients
will have different device preferences. Better adherence
has also been observed when patients are treated with
combination ICS/long-acting b2-agonists (LABA) therapy
compared with ICS alone (72.2% versus 40.5%, respectively,
pZ 0.001), possibly due to the positive reinforcing effects
of improved and more immediate symptom control with
combination therapy.62 More studies are necessary to fullyestablish the connection between the type of inhaler de-
vice and treatment adherence.
Frequency of dose administration is often described as a
contributing factor to poor adherence, and a high daily
frequency of inhaled drug administration (four times daily
versus twice daily) has been shown to negatively influence
adherence to medication in an asthma trial.63 A significant
correlation has also been demonstrated between patient
satisfaction with their inhaler and adherence (defined as
the extent to which patients were perceived to follow their
physician’s prescribing instructions/advice) in asthma,30
suggesting that the more satisfied the patient is with their
device, the more likely they are to be adherent to treat-
ment, and, therefore, are more likely to experience
improved clinical outcomes and quality of life. However,
correlations in this study were weak, potentially because
physicians often interpret patient adherence poorly.
Furthermore, as improved inhalation technique has been
shown to improve adherence to asthma therapy (possibly
due to the positive reinforcing effects of improved symp-
tom relief concurrent with improved medication adminis-
tration), it is crucial that repeated instruction on this point
is provided to patients from the outset.33,54
A recent report from the European Respiratory Society
and the International Society for Aerosols in Medicine rec-
ommends that patients remain on their current inhaler if
their disease is stable, rather than switching to another
device.64 A switch in devices can result in incorrect device
technique (because of lack of education and experience
with the new device), leading to suboptimal drug adminis-
tration, poor treatment adherence and, therefore,
decreased asthma control. In support of this, a recent study
demonstrated that asthma control worsened when the
inhaler was switched without patient consent.65 Given the
association between inhaler satisfaction and adherence, it
is essential that the patient is fully involved in the choice of
device, and that their preferences are taken into account
when considering a switch of inhaler. In line with this, it has
recently been demonstrated that there is a paucity of
guidance for the use of devices in asthma and COPD
treatment guidelines.66 Increased guidance on the use of
devices may improve physician awareness of relevant is-
sues, potentially improving treatment outcomes.Effect of adherence on clinical efficacy
The association between adherence to inhaled asthma and
COPD therapy and clinical effect varies in the literature.
Generally, good adherence is associated with better
symptom control in patients with asthma, including chil-
dren and adolescents.22,29,31,58,67e71 However, some
studies, including those in children and adolescents,72,73
have shown no correlation between adherence and
asthma control,74e76 while inconsistent associations have
also been noted between the two.47 Numerous factors may
be responsible for this variation, including population bias
and differences in adherence assessment and reporting
methods; however, there is general consensus that
improved adherence to asthma therapy improves clinical
outcomes. Overall, studies indicate that improved adher-
ence leads to improvements in lung function in patients
Adherence of inhaled therapies for asthma and COPD 1485with asthma,22,77 although some studies did not find any
such correlation.36,78
Good adherence is associated with reduced exacerba-
tion rates in patients with asthma19,79,80 and COPD.81 A sub-
analysis of the TORCH (Towards a Revolution in COPD
Health) study showed that good adherence to study medi-
cation in patients with COPD (nZ 6112) was associated
with lower mortality rates compared with poor adherence
(11.3% versus 26.4%).82 This effect was maintained over a 3-
year period, regardless of treatment (Table 2). In line with
this, a population-based cohort analysis demonstrated that
the asthma-related death rate decreased by 21% with each
additional canister of ICS used by a patient in the previous
year (Table 3).83 Whilst it is relatively easy to identify a
correlation between adherence and outcomes with ‘hard’
endpoints such as mortality, correlations are more difficult
to see with less clear-cut endpoints such as the more subtle
changes in disease control. Furthermore, the association
between adherence and mortality may be indirect,
contingent on fundamental patient characteristics that
underlie adherence (e.g., risk behaviour). However, the
available data indicate that improved adherence results in
improved medication delivery and, therefore, improved
clinical efficacy and better disease control.Effect of adherence on costs and health
outcomes
Good adherence is correlated with reductions in healthcare
utilisation in patients with asthma30,38,75,84 and COPD,81 as
well as in children and adolescents with asthma.39,69,72 In
contrast, COPD exacerbations are associated with an in-
crease in healthcare utilisation, providing an explanation for
the fact that exacerbations are a main cost driver in both
asthma and COPD; one British study showed that patients
who experienced an asthma attack incurred healthcare costs
3.5 times greater (costs per patient over a 1-year period)
than those who did not.85 Similarly, in patients with COPD,
exacerbations are thought to be responsible for 35e45% of all
healthcare costs associated with the disease.86 In support of
this, a retrospective study using a large administrative claims
database showed that higher adherence rates are correlated
with reduced urgent care usage (annual number of inpatient
days, inpatient visits and emergency room visits) in patientsTable 2 3-Year mortality rates in patients with COPD with
good or poor adherence.82
Therapy 3-Year mortality rates (%)
Good
adherence
Poor
adherence
Salmeterol 10.7 25.2
Fluticasone propionate 12.9 28.7
Combination salmeterol/
fluticasone propionate
9.5 24.9
Placebo 12.0 26.7
Good adherence was defined as an average adherence to study
medications of >80% over the whole period the subject was in
the study; poor adherence was defined as 80%.with COPD (nZ 55,076).81 However, studies have also
demonstrated no difference between patients with asthma
who are adherent and non-adherent to treatment in terms of
healthcare utilisation (emergency room visits), in both
adults31 and adolescents.78 As with any improvements in
clinical outcomes, patients in the latter two studiesmayhave
had milder forms of asthma, and, consequently, any re-
ductions in healthcare utilisation associated with disease-
related events may have been insufficient to offset the
possible increase in medication costs and/or physician visits
associated with improved adherence.
Costs associated with general healthcare39 and lost
productivity87 tend to be higher in patients with asthma
who are non-adherent to treatment versus those who are
adherent. However, one large retrospective observational
study demonstrated that savings generated by reductions in
high-cost events did not offset the increased drug costs for
more adherent patients with asthma, with the exception of
high-risk patients with more severe asthma.88 These results
support the suggestion that the cost benefit of improved
adherence may be more marked in patients with more se-
vere forms of respiratory disease. Additionally, it is possible
that significant cost savings are not seen early in the dis-
ease process (as exacerbations are more mild and thus less
costly to treat), but may be found as the disease pro-
gresses, with more severe exacerbations requiring more
expensive treatments. Consequently, to account for this
effect, economic analyses of treatments that potentially
slow disease progression should be designed to capture an
appropriate time period.
Quality of life is also presumed to increase in tandem
with adherence. Although the literature is somewhat
inconsistent, with some studies reporting no change in
quality-of-life scores despite improved adherence,74,87
overall, good adherence is associated with improvements
in health-related quality of life (generally through reduced
exacerbations and improved symptoms) in patients with
asthma30,33,77 and COPD,89 including adolescents.90Summary and discussion
Despite the range of effective pharmacological treatments
available for asthma and COPD, many patients still do not
achieve treatment goals, in part because of poor adherence
to therapy. Non-adherence to treatment is associated with
poor symptom control, higher healthcare utilisation and
healthcare costs, and reductions in health-related quality
of life. These findings are consistent with those in other
chronic disease areas such as cardiovascular disease and
diabetes mellitus.
In patients with hypertension, non-adherence and poor
persistence with antihypertensive medications are associ-
ated with uncontrolled hypertension, poor clinical
cardiovascular-related outcomes and increases in health-
care costs.91 A recent review estimated that only 50% of
hypertensive patients are adherent to their treatment
regimens after 1 year.92 Adherence rates of 36e93% and
73e86% have been shown in type 2 diabetes mellitus pa-
tients receiving oral antihyperglycaemic therapy or insulin,
respectively.11 Given the correlation between adherence
and clinical outcome for cardiovascular disease and
Table 3 Crude and adjusted rate ratios for death from asthma in relation to discontinuation from inhaled corticosteroid
usea.83
Corticosteroid use Case patients
(NZ 66)
Controls
(NZ 2681)
Crude rate
ratio
Adjusted rate
ratio (95% CI)b
Uninterrupted (%) 4.6 7.9 1.0 1.0c
Discontinued (%)
1e3 months before index date 19.7 9.0 3.9 4.6 (1.1, 19.1)
4e6 months before index date 4.6 6.3 1.3 1.8 (0.3, 10.9)
7e9 months before index date 4.6 5.3 1.7 1.6 (0.3, 9.4)
CI, confidence interval
a Index date for cases and matched controls was the date of the case patient’s death from asthma.
b Rate ratios are adjusted for age and sex; the number of prescriptions for theophylline, nebulised and oral b-adrenergic agonists and
oral corticosteroids the year before the index date; the number of canisters of inhaled b-adrenergic agonists dispensed in the year
before the index date; and the number of hospitalisations for asthma during the two years before the index date.
c Denotes reference group.
1486 M.J. Ma¨kela¨ et al.diabetes mellitus, it is unsurprising that adherence to
treatment and sustained disease control are associated
with reduced annual healthcare costs93; however, unfor-
tunately high rates of under-treatment and non-adherence
persist. In line with findings in asthma,25 adolescents (aged
10e20 years) with diabetes mellitus were more likely to be
poorly adherent and have worse glycaemic control than
younger and older patients in a systematic review.94 This
finding is important, as it suggests that adolescents may be
at greater risk of non-adherence, and therefore, at greater
risk of poor disease control and worse clinical outcomes.
The confirmation of this finding in another chronic disease
setting identifies this patient population as a target for
increased intervention to improve adherence. Further-
more, poor adherence has been demonstrated to be a sig-
nificant factor in asthma-related death and near-miss cases
in adolescents,95 as well as the presence of more severe
disease96 and poorer quality of life in this population.28
Targeting non-adherence is, therefore, particularly impor-
tant for physicians responsible for younger patients, pre-
dominantly adolescents, for whom issues related to image/
expectations, cost and convenience impact substantially on
adherence.28,78 It may also be appropriate for adolescents
to be moved from the care of a paediatrician to an adult
clinic in order to gain traction when attempting to modify
adherence behaviours.97 Limited clinical trial evidence for
adherence in older patients (aged 65 years) was available.
However, one recent review of asthma in the elderly98
suggested that older patients with asthma may intention-
ally decide not to adhere to treatment, generally because
of poor knowledge of the disease, treatment or the con-
sequences of poor adherence. As with younger patients,
older patients may also display non-intentional poor
adherence due to comorbidities or a combination of
cognitive and physical decline; for instance, impaired vision
or musculoskeletal conditions may affect their ability to use
an inhaler correctly.98 Furthermore, a letter to the Editor
of the Lancet published in 2006 concluded that assistance
by caregivers is an important strategy in combating poor
adherence to ICS therapy in elderly asthma patients with
complications (such as cognitive and motor dysfunction).99
Similarly, while there is a general understanding that pa-
tients prefer fewer daily medication doses, we did not
identify any clinical trials that have assessed this in acontrolled environment. However, two administrative
database assessments100,101 have shown that patients,
including adolescents and young adults,101 receiving once-
daily therapy for asthma are more adherent to treatment
than those prescribed twice-daily treatment.
Given the numerous factors driving non-adherence to
inhaled asthma and COPD therapy, there are many points at
which healthcare professionals could intervene to improve
adherence. Patient perception is an important target, as how
the patient feels about their illness, medication, inhaler and
even their healthcare professional can influence how likely
they are to adhere to their treatment regimen.18 Patient
education is also crucial; this can occur on multiple levels,
including the disease itself, the medication and the device.
Regimen convenience can also be targeted by physicians; a
variety of combination inhalers now exist, reducing the
number of inhalers patients must carry with them. For
example, patients receiving maintenance therapy who
require both ICS and LABA experience greater convenience
withfixed ICS/LABAcombination inhalers,which requireonly
two administrations per day compared with the more
frequent schedules indicated by older formulations.
It is crucial that patients are able to operate their inhaler
correctly, and this should be evaluated by a physician or
nurse during a clinic visit. A clear explanation of how to use
an inhaler is required,18 as patients may initially find using
different inhalers difficult and their understanding ofwritten
instructional materials will vary.102 To reinforce correct use
of the inhaler, it is important for the healthcare professional
to repeat these instructions at subsequent visits.33 Despite
the positive association between device satisfaction and
clinical outcome, there is no information to suggest any link
between adherence to specific devices and clinical health
outcomes or costs. Given the range of devices currently
available for asthma and COPD, such data are likely to be
clinically useful, as well as important for future pharma-
coeconomic analyses. Further research in this area would be
of great clinical relevance.
In general, good adherence to inhaled therapies is
correlated with reductions in healthcare resource utilisation
(including costs associated with direct healthcare and lost
productivity) in both asthma and COPD, and in adults, chil-
dren and adolescents. However, there is evidence to suggest
that the costs associated with adherence to asthma
Adherence of inhaled therapies for asthma and COPD 1487treatment are not offset in patients withmilder disease. The
reasons for this are unclear, but as increased adherence is
thought to be associated with a reduced economic burden,
this finding warrants further investigation to establish the
implications for future adherence interventions. One
possible explanation may be that any short-term economic
savings achieved through frequent changes of inhaler device
are actually offset over time, if they result in decreased
adherence and, subsequently, worse outcomes.
Conclusions
Suboptimal or non-adherence to inhaled therapies for
asthma and COPD is associated with poor symptom control,
higher healthcare utilisation and healthcare costs, and re-
ductions in health-related quality of life. The findings
reviewed here suggest that poor adherence to inhaled
therapies is common among patients with asthma and
COPD, and is particularly problematic in adolescents with
asthma. Furthermore, patient satisfaction with their
inhaler is positively correlated with improved adherence,
clinical outcomes and treatment costs. Given the growing
prevalence of these conditions in the young, this disparity
in adherence between adolescents and adults may have
significant consequences for healthcare costs, and society
in general, if the issue remains unaddressed. Additional
research is required to identify measures that can improve
adherence in order to address these questions.
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